A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Myelo 001 (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Acronyms MyeloConcept
- Sponsors Myelo Therapeutics
- 03 Jul 2017 Status changed from active, no longer recruiting to completed.
- 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2017.